Jedd D. Wolchok

6 ta ish

Cornell University

1. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

   F. Stephen Hodi, Steven O’Day, David F. McDermott +26

   MaqolaOAOchiq kirish201010 iqtibos

   ABIABI:AkademIndex/2026.other.121325

2. Cancer immunotherapy using checkpoint blockade

   Antoni Ribas, Jedd D. Wolchok

   Sharh maqolaOAOchiq kirish20184 iqtibos

   ABIABI:AkademIndex/2026.other.051032

3. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

   James Larkin, Vanna Chiarion‐Sileni, René González +28

   MaqolaOAOchiq kirish20153 iqtibos

   ABIABI:AkademIndex/2026.other.170114

4. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

   Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González +30

   MaqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.082822

5. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

   Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal +33

   MaqolaOAOchiq kirish20162 iqtibos

   ABIABI:AkademIndex/2026.other.102835

6. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

   Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider +26

   Maqola20182 iqtibos

   ABIABI:AkademIndex/2026.other.769170